Short interfering RNA induced generation and translation of stable 5' mRNA cleavage intermediates by Singhania, Richa et al.
  	

Short interfering RNA induced generation and translation of stable 5’ mRNA
cleavage intermediates
Richa Singhania, Sandra Pavey, Elizabeth Payne, Wenyi Gu, Jennifer
Clancy, Luqman Jubair, Thomas Preiss, Nicholas Saunders, Nigel A.J.
McMillan
PII: S1874-9399(16)30126-2
DOI: doi: 10.1016/j.bbagrm.2016.06.005
Reference: BBAGRM 1045
To appear in: BBA - Gene Regulatory Mechanisms
Received date: 30 March 2016
Revised date: 14 June 2016
Accepted date: 15 June 2016
Please cite this article as: Richa Singhania, Sandra Pavey, Elizabeth Payne, Wenyi
Gu, Jennifer Clancy, Luqman Jubair, Thomas Preiss, Nicholas Saunders, Nigel
A.J. McMillan, Short interfering RNA induced generation and translation of sta-
ble 5’ mRNA cleavage intermediates, BBA - Gene Regulatory Mechanisms (2016), doi:
10.1016/j.bbagrm.2016.06.005
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
1 
 
  
 
Short interfering RNA induced generation and translation 
of stable 5’ mRNA cleavage intermediates 
 
 
 
Richa Singhania
1
, Sandra Pavey
1
, Elizabeth Payne
1
, Wenyi Gu
1
, Jennifer Clancy
2
, Luqman 
Jubair
3
, Thomas Preiss
2
, Nicholas Saunders
1
, Nigel A.J. McMillan 
1,3, * 
 
 
1
The University of Queensland Diamantina Institute, University of Queensland, Brisbane, 
Australia  
 
2
The John Curtin School of Medical Research, The Australian National University, Canberra, 
Australia 
 
3 
Menzies Health Institute Queensland and School of Medical Science, Griffith University, 
Southport, Australia. 
 
 
* Corresponding Author 
 
Email: n.mcmillan@griffith.edu.au 
 
 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
2 
 
 
 
 
Abstract  
Sequence-specific degradation of homologous mRNA is the main mechanism by which 
short-interfering RNAs (siRNAs) suppress gene expression. Generally, it is assumed that the 
mRNA fragments resulting from Ago-2 cleavage are rapidly degraded, thus making the 
transcript translation-incompetent. However, the molecular mechanisms involved in the post-
cleavage mRNA decay are not completely understood and the fate of cleavage intermediates has 
been poorly studied. Using specific siRNAs and short-hairpin RNAs (shRNAs) we show that the 
5’ and 3’ mRNA cleavage fragments of human papilloma virus type 16 (HPV-16) E6/7 mRNA, 
over-expressed in cervical malignancies, are unevenly degraded. Intriguingly, the 5’ mRNA 
fragment was more abundant and displayed a greater stability than the corresponding 3’ mRNA 
fragment in RNAi-treated cells. Further analysis revealed that the 5’ mRNA fragment was 
polysome-associated, indicating its active translation, and this was further confirmed by using 
tagged E7 protein to show that C-terminally truncated proteins were produced in treated cells. 
Overall, our findings provide new insight into the degradation of siRNA-targeted transcripts and 
show that RNAi can alter protein expression in cells as a result of preferential stabilization and 
translation of the 5’ cleavage fragment. These results challenge the current model of siRNA-
mediated RNAi and provide a significant step forward towards understanding non-canonical 
pathways of siRNA gene silencing. 
 
Highlights 
 RNA interference does not result in the immediate degradation of mRNA following 
cleavage 
 The 5’ cleavage product of mRNA has a longer half-life than the 3’ product 
 The 5’ cleavage product is translated into truncated protein 
 Cleavage can occur on the ribosome during translation.  
 
Keywords:  siRNA, shRNA, RNAi, mRNA cleavage, mRNA decay 
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Introduction 
Gene expression in eukaryotes is governed by the relative rates of mRNA transcription, 
translation and degradation. There is mounting evidence to show that small RNAs are key 
modulators of eukaryotic gene expression. The transcriptional and post-transcriptional regulatory 
pathways orchestrated by various small RNAs are collectively termed as RNA interference 
(RNAi) or gene silencing. To date, many species of small RNAs have been described and the list 
continues to expand. Short-interfering RNAs (siRNAs) are ~21 nucleotide long RNA molecules 
that interfere with the expression of cytoplasmic mRNAs by mediating endonucleolytic cleavage 
(1). Functional siRNAs can either be delivered into the cell cytoplasm extracellularly or else 
generated intracellularly by Dicer-processing of short-hairpin RNAs (shRNAs). The 
posttranscriptional gene silencing mediated by siRNA relies on the combined outcome of the 
reduction in the target mRNA transcripts and the repression of translation of encoded protein.  
Firstly, the siRNA duplex unwinds and the guide strand associates with Argonaute 2 (Ago2) 
protein, and together they form core of the effector complex known as the RNA-induced 
silencing complex (RISC). Next, the siRISC is recruited to the target mRNA transcript through 
base-pairing interactions and ultimately interferes with the target protein expression by causing 
mRNA cleavage and decay (2). Although, their origin and mechanism of action are well 
characterized, molecular details of post-cleavage mRNA decay remain to be fully elucidated. In 
this study we have attempted to explore the downstream events of siRNA-mediated mRNA 
cleavage.   
Our current understanding of siRNA action is that the slicer activity of Ago2 in siRISC 
directs the cleavage of target mRNA between 10
th
 and 11
th
 nucleotide of the base paired region 
(2) and as a result, a capped 5’ and a poly(A) tailed 3’ mRNA fragment will be created, each 
bearing an unprotected end. The RNAi cleavage fragments are targeted by the general cellular 
mRNA degradation machinery for complete destruction from their exposed ends (3). There are 
two major conserved mRNA degradation pathways in eukaryotes, which are initiated by 
shortening of the poly(A) tail. Deadenylated mRNAs can either be digested by the 3’-to-5’ 
exonuclease activity of a multisubunit complex called the exosome, or else can undergo DCP1/2-
directed decapping prior to being degraded in a 5’-to-3’ direction by the XRN1 exonuclease (4). 
This would suggest a model for siRNA-cleaved mRNAs whereby the 5’ cleavage fragment is 
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degraded by the exosome from its free 3’ end while the 3’ cleavage fragment is degraded by 
XRN1 from its free 5’end. Experimental evidence supports this model with knockdown studies 
in Drosophila showing that the 5’ fragment is a substrate for 3’-to-5’ exonuclease activity of the 
exosome (5). Perfectly matching miRNAs mimic siRNA action to mediate target mRNA 
cleavage and sometimes in such instances the 5’ cleavage fragment is modified by the addition 
of a tail of uridines or adenosines at the site of cleavage in order to accelerate the exosome-
mediated decay (6). Loss of XRN1 in Drosophila S2 cells leads to stabilization of the 3’ 
fragment (5). Similarly, loss of XRN4, a plant homolog of XRN1, leads to accumulation of the 
3’ miRNA cleavage product in Arabidopsis (7).  
In eukaryotic cells, sub-microscopic cytoplasmic foci known as processing or P-bodies 
(PBs, also referred to as GW-bodies) are considered to be major sites of mRNA turnover. These 
mRNP granules arise due to accumulation of RNA-binding proteins, mRNA decay factors, but 
are devoid of translation factors (except eIF4E) and ribosomes (8, 9). It is now evident that PBs 
serve as intracellular sites for RNAi (10, 11), suggesting that RISC activation and the execution 
of terminating steps of RNAi pathway occur in PBs. Although PB environment offers a kinetic 
advantage, they are not essential for the execution of RNAi (12). PBs do not participate in 
translation (13), however, they are not dead ends. Some of the translationally inactive mRNPs 
may be committed to immediate decapping and degradation (14) while the rest may exit to 
associate with polysomes and resume translation (15). The ability of mRNA to exist in dynamic 
equilibrium between a translationally active state (polysomes) and a translationally repressed 
state (PBs) suggests that these processes are interconnected (16).  
In mammalian cells mRNA degradation has been observed to be neither rapid nor 
complete with siRNA-mediated cleavage reported to result in the generation of partially stable 5’ 
or 3’ mRNA fragments (17-20). Indeed, we have previously shown that truncated proteins can be 
translated from the 5’ end of shRNA-targeted mRNA (21).  However, the details by which 
cleaved products can result in truncated proteins remain unclear.  
 
The link between mRNA abundance, stability, and translation remains to be clearly 
elucidated in the presence of a siRNA stimulus. Therefore, the purpose of the current study was 
to investigate the fate of siRNA-generated mRNA cleavage fragments and understand how 
si/shRNA influences the steady-state levels, half-lives and translation status of the cleavage 
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intermediates. Using the human papillomavirus type 16 (HPV-16) E6/7 mRNA as a model, we 
report that siRNA-generated 5’ mRNA fragment had higher steady-state levels and was found to 
persist longer than the 3’ mRNA fragment. Moreover, 5’ cleavage intermediates were present in 
polysomes and were translated to produce truncated E7 protein products. Our findings help to 
understand the molecular consequences of siRNA knockdown and highlight a previously 
uncharacterised decay pathway of cleavage intermediates that may alter the therapeutic outcomes 
of RNAi.  
 
Materials and Methods 
Cell culture - TC-1, HeLa and CaSki cells (from the ATCC) were maintained in DMEM 
(Invitrogen) supplemented with 10% heat-inactivated fetal calf serum (Sigma) and 1% antibiotic 
mixture of penicillin G, streptomycin sulfate and L-Glutamine (Gibco-Invitrogen).  
Plasmid transfection - The FLAG-E7-MYC sequence was cloned into pJ204 (DNA 2.0, 
CA) and then sub-cloned into pcDNA3 as a HindIII-EcoRI fragment. Cells were transiently 
transfected with the construct using Lipofectamine 2000 (Invitrogen), according to 
manufacturer’s instructions. 
siRNA transfection and shRNA lentiviral transduction - Cells were transiently transfected 
with 40 nM siRNA duplexes (Integrated DNA Technologies) using Oligofectamine (Invitrogen), 
as per manufacturer's protocol. The shRNA expression cassettes were cloned into pLentiLox3.7 
(pLL) vector to generate stable cell lines. Transduction efficiency was determined by 
FACSCanto flow cytometer (BD Biosciences) and GFP positive cells sorted using MoFlo cell 
sorter (Beckman Coulter). The sequences of the siRNAs and shRNAs are listed in Table S1. 
Semiquantitative RT-PCR - PCR was performed in 25 μL volume consisting of PCR 
buffer (10X), dNTP mix (10μM), primers (10μM), Taq DNA polymerase, and cDNA (1:10 
dilution) under the following PCR profile: 5 min initial denaturation at 95˚C, followed by 20 
cycles of denaturation (94˚C), annealing (58-62˚C) and extension (72˚C), plus a final extension 
at 72˚C for 5 min. DNA was electrophoresed n 1.5% agarose gel and visualized by UV 
transillumination.  
Quantitative RT-PCR (qPCR) - Total RNA was prepared from cells using the TRIzol
®
 
reagent (Invitrogen) according to the manufacturer's protocol. Reverse transcription reaction was 
carried out on DNase-treated RNA using Omniscript reverse transcription kit (Qiagen) and an 
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equimolar ratio of oligo(dT) primer and random hexamers. The resulting cDNA was amplified 
with gene-specific primers (Table S2) and quantified using FastStart Universal SYBR Green 
(Roche Applied Science) on AB 7900HT real-time PCR system (Applied Biosystems). 
Comparative Ct (∆∆Ct) method was used for performing relative quantitation of gene 
expression. Absolute quantitation was done by comparing the Ct values of samples with a 
standard curve generated by known amounts of pcDNA3-HPV16 and pCMV6-GAPDH-GFP 
plasmids. 
mRNA half-life estimation - Total RNA was extracted from cells harvested at different 
time points post actinomycin D (5 µg/mL, Sigma) treatment and reverse transcribed into cDNA. 
The amount of mRNA at each time point was analyzed by qPCR and expressed as a percentage 
of the total amount of mRNA at time 0 and was plotted against time. The data was analyzed by 
exponential non-linear regression (one-phase decay) analysis to determine the best-fit line. Half-
lives were determined by extrapolating the best fit line to the point where it crosses the 50% 
mRNA onto the X axis.  
Polysome analysis - Cells were treated with 100 μg/mL cycloheximide (Sigma) for 3 min 
and lysed in a buffer containing 20mM HEPES (pH 7.6), 125 mM KCl and 5mM MgCl2, 2mM 
DTT, 0.5mM PMSF, 100 units/mL of RNase inhibitor, 0.5% NP40, 100 μg/mL CHX and 
cocktail of protease inhibitors on ice. Cell lysates were fractionated on a 17.5–50% (w/v) sucrose 
gradient, followed by centrifugation in SW41Ti rotor at 35,000 r.p.m. for 2h 15min (22). The 
gradient was fractionated on a density gradient fractionator (Teledyne ISCO) and polysome 
profiles were monitored by UV absorbance at 254nm. To analyse the mRNA distribution on 
polysomes, RNA extracted from each gradient fraction was subjected to qPCR. 
Stem loop qPCR - Reverse transcription (RT) reactions were carried out using 500 ng of 
RNA along with 1X RT buffer, 0.25 mM dNTPs, 0.3 U/µL reverse transcriptase, 0.25 U/µL 
RNase inhibitor and 50 nM stem loop RT primer (23) and successively incubated for 30 min at 
16°C, 30 min at 42°C and 5 min at 85°C. The RT product was amplified with 1X Taqman 
universal PCR master mix (Applied Biosystems), 0.2 M Taqman probe, 1.5 µM forward primer 
and 0.7 µM reverse primer using standard qPCR thermal profile and performed on an AB 
7900HT real-time PCR system (Applied Biosystems). The sequences of probes and primers are 
listed in Table S3. 
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Immunofluorescence - Transfected cells were fixed with 4% paraformaldehyde for 30 
min, washed and permeabilized with 0.1% Triton X-100. Cells were immunolabelled using 
fluorescently conjugated antibodies against FLAG and MYC tags (1:200; Alexa Fluor 555 and 
647 conjugates, respectively; Cell Signaling Technologies) and incubated along with DAPI 
(1:1000). Coverslips were mounted using ProLong Gold (Invitrogen), observed with Zeiss 
LSM510 laser scanning confocal microscope (Carl Zeiss) under a ×63 oil objective and analyzed 
by ImageJ software. 
Western Blotting. Twenty-four hrs after transfection cells were treated with MG132 
(Sigma) for 14 hours before lysis in RIPA buffer and Halt protease inhibitor (Thermo Scientific). 
Extracts were incubated for 60 min at 4°C with mouse anti-FLAG Tag (Cell Signaling 
Technologies) before A/G magnetic beads (BioLabs) were added an incubation continued 
overnight.  Following washing proteins were solubilised SDS loading buffer and run on 16% 
Tris-tricine gels before transfer and detection using rabbit monoclonal anti-flag primary antibody 
(Cell Signaling Technologies). 
Statistics.  Data are presented as mean or mean ± standard error of the mean (SEM). An 
unpaired Student's t-test (two-tailed, p ≤ 0.05) was used to determine statistically significant 
differences. 
 
 
Results 
RNAi cleavage results in preferential degradation of the 3’ mRNA fragment.  RNAi 
efficiency, as measured by the loss of full-length target mRNA, does not allow one to determine 
the potential presence and abundance of the resulting 5’ and 3’ mRNA cleavage products. To 
explore the fate of mRNA cleavage fragments generated following shRNA treatment, we utilized 
two shRNAs targeting the HPV-16 E6/7 mRNA, shE6 and shE7 (21) and a range of PCR primer 
pairs specific to various regions of the mRNA (Fig 1A). The E6/7 mRNA was highly reduced in 
TC-1 cells (murine cells transform with Ras, and E6/7) stably expressing each shRNA, as 
reported by the full-length PCR amplicon 1 (Fig. 1B). However, utilising primers specific to the 
5’ and 3’ ends of the mRNA (amplicons 2 and 3, respectively) we observed a different outcome. 
The 5’ and 3’ ends of E6/7 mRNA showed levels of reduction much less than the full-length 
mRNA upon shE6 and shE7 treatment, while cells treated with control shRNA (shNS-1) showed 
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no effect (Fig. 1B). This suggested that specific shRNA treatment results in delayed degradation 
of the cleaved mRNA in mammalian cells.  Analysis using quantitative reverse transcription 
PCR (qPCR) using specific 5’ and 3’ end primer sets matched for size and amplification 
efficiency confirmed that unequal degradation of the cleavage fragments was occuring (Fig. 1C). 
We observed that the 5’ fragment (amplicon 4) had higher steady-state levels compared to the 3’ 
fragment (amplicon 5) and the slice-site specific mRNA (amplicons 6/7). The same outcome was 
observed with E7 specific siRNAs (Figure S1), indicating that this was not a shRNA-only 
phenomenon.  
In order to understand the degradation events in more detail we next used PCR amplicons 
targeting regions within each predicted fragment (amplicons 4, 6 and 8 for 5’ fragment and 
amplicons 8, 7 and 9 for 3’ fragment). Using shE7 as the most 3’ target site, the 5’ fragment 
appeared to be degraded in the 3’-5’ direction given the reduced length of the 3’ amplicons 6 and 
8 compared to the 5’ fragment of amplicon 4. (Fig. 1D). Upon shE6 treatment, mRNA levels 
reported by amplicons 8 and 9 are much less abundant than those reported by amplicon 7, 
suggesting that the 3’ fragment is subjected to dual degradation in both 5’-to-3’ as well as 3’-to-
5’ direction (Fig. 1E).  
The 5’ fragment is longer-lived than the 3’ mRNA fragment. As abundance only reflects a 
snapshot of steady state mRNA levels, we next examined the half-lives (t1/2) of mRNA fragments 
following si/shRNA cleavage. The mRNA decay was monitored in cells harvested at various 
time-points post actinomycin D treatment by qPCR using 5’ end (amplicon 4) and 3’ end 
(amplicon 5) primer sets. The E6/7 mRNA exhibited a t1/2 of ~5 hours in control shRNA-treated 
cells (Fig. 2A), consistent with previous reports (24, 25). Treatment with E6/7-specific shRNAs 
resulted in a 2-3-fold decrease in the t1/2 of full-length mRNA (Fig. 2A). In non-specific shRNA-
treated cells the apparent t1/2 reported by 5’ and 3’ specific amplicons were similar, ~5 h (Fig. 
2B) and was in agreement with the t1/2 of full-length mRNA. Strikingly, the 5’ mRNA fragment 
exhibited a t1/2 almost twice as long as the 3’ mRNA fragment in cells treated with specific 
shRNAs (Fig. 2C). Treatment with E7 specific siRNAs yielded similar results (Figure S2). To 
our knowledge this is the first study highlighting t1/2 differences between the products of 
si/shRNA endonucleolytic cleavage in mammalian cells.  
The 5’ mRNA fragment is associated with polysomes. One consequence of the relative 
stability of the 5’ mRNA fragment is the potential for translation to occur.  To investigate this, 
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mRNA distribution on polysomes was analysed by density sucrose gradients. After a brief 
treatment with cycloheximide (CHX), cytoplasmic extracts of TC-1 cells were centrifuged 
through 17.5-50% gradients and RNA samples recovered from polysome fractions were analysed 
by qPCR to estimate the levels of 5’ and 3’ mRNA fragments. The sedimentation profiles of 
CHX-exposed control and shE6-treated cells showed that most of the mRNA-ribosome 
complexes were distributed in the polysome-bound fractions (Fig. 3A). Upon treatment with 
shE6 we observed that the 5’ end of the E6/7 mRNA was associated with translating ribosomes 
but the 3’ end could not be detected (Fig. 3B – shE6). This was a specific effect as both mRNA 
ends could be detected when non-specific shRNA was used (Fig. 3B – shNS-1).  
Controls to confirm whether mRNA was associated with polysomes, by preparing cell 
lysates in the presence of EDTA indicated the majority of β-actin mRNA, which served as an 
internal experimental control, was concentrated in the non-translating monosomal fractions 
(Figure S3). We found that the full-length E6/7 mRNA was bound to less number of ribosomes, 
consistent with its shorter length and its translation efficiency was reduced upon specific shRNA 
treatment (Figure S4).  
The specific 5’ mRNA fragment is present in total and polysomal RNA - To provide direct 
evidence that the 5’ fragment present in polysomes was the specific, shE6-directed 5’ cleavage 
product rather than a consequence of a random degradation event, we undertook a Taqman-based 
stem-loop RT-PCR assay, originally described for detection of miRNA (23) and siRNA (26) 
molecules (Fig. 4A). In this method, a stem-loop primer binds to the specific 5’ cleavage product 
at the 3’ cleavage site and primes reverse transcription. To ensure only the specific shRNA-
generated cleavage product was detected; a Taqman qPCR was performed using an E6/7-specific 
forward primer, a probe spanning the specific ligation site, and a loop-specific reverse primer. 
Using this assay we were able to detect the specific 5’ cleavage product only in the total and 
polysomal RNA samples obtained from cells treated with shE6 but not in control cells (Fig. 4B). 
Overall, polysome and stem-loop Taqman qPCR analyses showed that the specific 5’ shE6-
cleavage intermediate co-sedimented with polysomes, suggesting active translation.  
C-terminally truncated proteins are expressed after RNAi treatment - Finally, to establish 
a direct link between the generation and translation of 5’ cleavage fragments, we created a 
construct that expressed an in-frame FLAG tag at the 5’ end of the HPV16 E7 gene and a MYC 
tag at the 3’ end (Fig. 5A), so that the FLAG and MYC tags serve as surrogate markers for the N 
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and C-termini of the E7 protein, respectively. We hypothesized that upon shRNA cleavage 
overall E7 protein levels would decrease but there would be a higher expression of FLAG tag 
compared to MYC tag due to the postulated translation from the 5’ end of mRNA. Cells were 
treated with MG132 in order to block potential proteasomal turnover of truncated proteins (27). 
Using antibodies against FLAG and MYC, we observed a similar intensity of FLAG and MYC 
signals in untreated and control shRNA (shNS-1 and shNS-2) treated cells (Fig. 5B). In shE7 
treated cells, while the overall levels of E7 protein was reduced, there was a marked difference in 
the FLAG/MYC intensity with a shift towards FLAG signal intensity (Fig. 5B). Since E7 protein 
is mainly localized in the nucleus (28), nuclear fluorescence intensities were measured. The ratio 
of mean nuclear intensities of FLAG signal over MYC signal was close to 1 in control cells but 
in shE7 treated cells, the ratio increased to more than 2 (Fig. 5C), reflecting preferential 
translation of the 5’ end of E7 mRNA. Similar experiments using siRNAs against E7 resulted in 
the same pattern of expression (Fig S5).  Finally, we stably transfected the FLAG-HPV16 E7-
MYC expression construct into HeLa cells (which expresses HPV18 E7) and treated these cells 
with 16E7-specific siRNA, si16E7, and MG132 before using anti-FLAG to immunoprecipitate 
any resulting full length or 5’ truncated E7. We observed truncated E7 protein only in cells 
treated with si16E7 but not in cells treated with control siRNA or untreated (Fig. 6).  The 
products were specifically FLAG-E7 as no proteins were observed in HeLa cells expressing non-
tagged 16E7. Overall this data are consistent with the hypothesis that truncated E7 protein is 
translated from the 5’ end of RNAi-cleaved mRNA. 
 
DISCUSSION 
Generally, short-interfering RNAs (siRNAs) are believed to trigger rapid mRNA 
degradation via cleavage within the binding region, but comprehensive studies have not yet been 
conducted to chase the cleavage intermediates to prove this point. Here, we have investigated the 
fate of HPV-16 E6/7 mRNA after treatment with homologous shRNAs and siRNAs in TC-1 and 
CaSki cervical cancer cells, respectively. By comparing the steady state levels, stability and 
translation profiles we show that RNAi treatment triggers neither rapid nor complete mRNA 
degradation.  Rather it results in the generation of a 5’ cleavage fragment that is more stable than 
its 3’ counterpart, and this fragment is translated into C-terminally truncated protein products. To 
our knowledge, this is the first detailed study to show this phenomena. It also explains the 
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mechanistic basis for our previously published work showing RNAi alters immune presentation 
of ovalbumin (OVA) by increasing the level of the CTL epitope found in the 5’ end of RNAi-
targeted mRNA (21).  While our work here is only with HPV16 E6/7 mRNA, when combined 
with our previous work it suggests this phenomena may be a common attribute of all RNAi.  
The E6/7 mRNA abundance was considerably repressed upon RNAi targeting but a 
corresponding reduction in the cleavage products was not observed (Fig. 1). The data showed 
that si/shRNA cleavage led to unequal degradation of the cleavage products, with higher steady-
state levels of the 5’ fragment. Moreover, qPCR data provided some initial clues about a 
progressive degradation reaction of the 3’ fragment (Fig. 1D and 1E). The rationale behind such 
ambiguity remains largely undefined at this stage but it raises a possibility that the 5’ fragment 
might be temporarily protected from exosome degradation. Indeed, previous observations 
support this. For example, cleavage mediated by perfectly complementary let-7 miRNA resulted 
in a stable 5’ fragment lacking a poly(A) tail (17). However, others have shown that the 3’ 
siRNA cleavage fragments persist after cleavage, although it was observed that this does not 
occur for all mRNAs for reasons not yet clear (18, 20). 
The 5’ cap and 3’ poly(A) tail are critical for mRNA stability (29, 30) and translation 
(31), and the absence of any one of them alter mRNA turnover rates. We found that si/shRNA-
mediated cleavage leads to differential stability of cleavage products with the 5’ mRNA decay 
intermediate persisting in the cell longer than its 3’ counterpart (Fig. 2C-2E). We speculate that 
the presence of cap structure, mRNA secondary structure and/or translation factors might block 
access to the exosome but this remains to be proven.  A likely outcome of greater stability of the 
5’ fragment could be preferential translation into truncated protein.  While we have previously 
shown that cleaved mRNA can be translated (21), it is not clear how this might occur. Moreover, 
efficient ribosome loading usually requires a cap and a poly(A) tail (31). Thus, it is difficult to 
envisage how a capped, but poly(A)-less, 5’ fragment might be loaded onto the translation 
apparatus. One possibility is that cleavage might be occurring on already translating mRNA, 
perhaps in a manner similar to how miRNAs interact with mRNA (32, 33). We showed the 5’ 
mRNA fragment was loaded on polysomes (Fig. 3 and 4).  This suggests that mRNA may enter 
the RNAi pathway at a stage closer to translation, when the ribosomes are already bound to the 
mRNA. This is consistent with the previous observation in Drosophila S2 cells, which showed 
that 5’ mRNA fragments generated as a result of double-stranded RNA (dsRNA) cleavage were 
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translated prior to their decay (5). The 5’ cleavage products should, theoretically, be in frame but 
lack a stop codon; resembling aberrant transcripts that are recognized and targeted for 
destruction by the non-stop decay (NSD) mechanism (34). Given that NSD events take place on 
polysomes (34) it is likely that translationally dead-end 5’ fragments could give rise to C-
terminally truncated protein products. This idea is consistent with the presence of increased 
levels of FLAG-tagged truncated protein products in RNAi treated cells (Fig. 5 and 6). At this 
stage it is difficult to say whether translation of the 5’ fragment is a result of its higher stability 
or whether its association with the translation machinery offers a steric hindrance to the 
exosome, thus, making it more stable. Previous studies using antisense oligonucleotides have 
shown that RNase H-generated 3’ cleavage intermediates are translated into N-terminally 
truncated proteins (35, 36), contradictory to what our findings indicate for the fate of Ago2-
generated cleavage intermediates, but, mechanistic differences exist between antisense- and 
RNAi-mediated endonucleolysis. 
Our results suggest possibly two distinct models by which siRNA silencing might affect 
the cytoplasmic mRNA levels. The first model is that such translation could occur via transport 
of RNAi-cleaved 5’ fragments from P-bodies (PBs) to polysomes, a model consistent with 
previous studies showing full-length mRNA can do this (15). Spatial organization in P-bodies 
may selectively render the 3’ fragments susceptible to XRN1 degradation. Support for this idea 
is lent by studies showing co-localisation of XRN1 (but not the exosome components) with PBs 
(37). The alternative model is that siRISC assembly and mRNA cleavage occurs directly on the 
translating mRNA pool. In support of this argument, Ago1 (also known as eIF-2C), in the 
context of miRNAs has been found associated with polysomes in mammalian cells (38-40). 
Since translation has already begun at the 5’ end, post cleavage ribosomes would complete the 
round of translation and stall at the 3’ end of the 5’ fragment, as described for NSD. In order to 
release the occupied ribosomes for cellular protein synthesis, such fragments may be subjected to 
exosome degradation (41). This is also consistent with the observed stabilization of the 5’ 
fragment (Fig. 2) where the presence of translation factors/ribosomes might block access to the 
exosome. One major question that remains unresolved is whether Ago2 cleavage occurs on 
nascent mRNA in cytoplasm, on siRNA bound non-translating mRNPs in PBs or else on 
polysome bound mRNAs in the cytoplasm. Alternatively, siRNA silencing might be a combined 
outcome of such events.  
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It is known that plants utilize RNA silencing pathways to directly respond to virus attack. 
Mammals having evolved an elaborate immune system do not appear to use the RNAi machinery 
to directly respond to pathogens or tumours. However, our previous work has shown that C-
terminally truncated proteins behave as gain-of-function mutants and RNAi, if appropriately 
targeted, can augment the immune surveillance mechanisms already in place (21). Thus, the 
RNAi system may directly influence immunity to target proteins. Having established these 
insights we can now focus on consequences of RNAi-directed production of truncated protein 
products in other biological systems, including potential dominant negative effects. In 
conclusion, selective stabilization and translation of the 5’ mRNA fragment suggest that siRNA 
targeted mRNA enter into an uncharacterized decay pathway. While further work is required, our 
study provides a novel insight into RNAi, particularly into the way in which mRNA is fed into 
the siRNA pathway for posttranscriptional gene regulation.  
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FIGURE LEGENDS  
 
Fig 1. shRNA cleaved mRNA is not evenly degraded. Total RNA samples were isolated from 
control (untreated and non-specific shRNA, shNS-1) or E6/7 targeting shRNA (shE6 and shE7) 
treated TC-1 cells, and analyzed by semi-quantitiative RT-PCR and quantitative RT-PCR 
(qPCR) to assess the levels of 5’ and 3’ ends of E6/7 mRNA. (A) Schematic representation of the 
cutsites of E6/7 specific-shRNAs and PCR amplicons amplifying different regions of E6/7 
mRNA. (B) Representative gel image of semi-quantitiative RT-PCR products (Primer scheme 
B). (C) Steady-state levels of the 5’ and 3’ ends of E6/7 mRNA determined by absolute qPCR of 
cDNA from 40ng of total input RNA  (Primer scheme C). (D) Abundance of different regions of 
5’ fragment created after shE7 cleavage by absolute qPCR (Primer scheme D) of cDNA from 
40ng of total input RNA. (E) Abundance of different regions of 3’ fragment created after shE6 
cleavage by absolute qPCR (Primer scheme E) of cDNA from 40ng of total input RNA. Mean ± 
SEM; n = 3. 
 
Fig 2. The 5’ cleavage product is more stable than the 3’ cleavage product in shRNA treated 
cells. Decay profiles of the full-length E6/7 mRNA (A) and the 5’ and 3’ ends of E6/7 mRNA in 
TC-1 cells treated with non-specific shRNA, shNS-1 (B); and E6/7 specific shRNAs, shE6 and 
shE7 (C). Cells were cultured for indicated time points in the presence of actinomycin D (Act D, 
5 μg/mL) prior to harvesting for RNA extraction. E6/7 mRNA expression was analysed by qPCR 
(∆∆Ct method), relative to untreated 0 h sample and normalized against housekeeping gene, β-
actin. Primers described in Fig. 1A [amplicons 6/7 (full-length mRNA), 4 (5’ end) and 5 (3’ 
end)] were utilized for qPCR. E6/7 mRNA expression at 0 h time-point was set to 100% in each 
individual experiment to determine half-life values. The graphs show the percentage of mRNA 
remaining (y-axis) plotted against time post Act D treatment (x-axis). Mean ± SEM; n = 3. P-
value <0.001 (**) or <0.0001 (***), comparing each treatment to shNS-1 controls (A) or 
between the 5’ and 3’ ends of each treatment (C).  
 
Fig 3. The 5’ cleavage product is associated with polysomes. (A) Representative polyribosomal 
profiles of TC-1 cells treated with non-specific shRNA, shNS-1 and E6 targeting shRNA, shE6. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
19 
 
Cytoplasmic lysates, prepared from cells treated with cycloheximide (CHX) were fractionated on 
a sucrose density gradient. Absorbance was recorded at 254 nm during collection of each 
fraction (B) Relative distributions of the 5’ and 3’ ends of E6/7 mRNA in gradient fractions of 
CHX treated shNS-1 and shE6 treated TC-1 cells. Each fraction was processed for RNA 
extraction and subsequently analysed by relative qPCR (∆∆Ct method) utilizing 5’ and 3’ 
reporter primers, described in Fig. 1A (amplicons 4 and 5). The amount of E6/7 mRNA in each 
fraction was relative to the amount of spike-in RNA (in vitro transcribed B. subtilis RNA). Mean 
± SEM; n = 1, three technical replicates. P-value <0.0001 (***) comparing the 5’ and 3’ ends of 
each treatment.  
 
 
Fig 4. The specific 5’ cleavage product can be detected in total and polysomal RNA by stem-
loop qPCR. (A) Schematic depicting Taqman based stem-loop RT-PCR strategy to detect the 
presence of 5’ cleavage products. Total or polysomal RNA (500 ng) was reverse transcribed 
using a stem loop RT primer that binds specifically to the last 4 nucleotides on 3’ end of the 5’ 
cleavage fragment. The PCR product was amplified from cDNA using Taqman probe and 
primers.  (B) Stem loop qPCR detection of 5’ cleavage product in positive control, negative 
controls (untreated and non-specific shRNA, shNS-1) and shE6 treated TC-1 cells. The positive 
control sample was prepared by digesting pcDNA3-16E7 plasmid with BanII, followed by in 
vitro transcription to generate a fragment resembling the 5’ cleavage product. NTC - no template 
control. P-value  <0.0001 (***), comparing each treatment to the positive control  
 
 
Fig 5. C-terminally truncated proteins can be detected in shRNA treated cells. (A) Schematic 
depicting E7 gene tagged with FLAG tag on the 5’ end and MYC tag on the 3’ end. The FLAG-
E7-MYC construct was cloned into pcDNA3 for transient transfections. The cutsite of E7-
specific shRNA, shE7 has been indicated. (B) The expression of FLAG-E7-MYC protein in TC-
1 cell lines stably expressing pLL 3.7 vector only (empty vector); non-specific shRNAs, shNS-1 
and shNS-2; and shE7. The FLAG and MYC protein expression was visualised by confocal 
microscopy, using FLAG (red fluorophore, Alexa Fluor 555) and MYC (green fluorophore, 
Alexa Fluor 647) antibodies. Magnified images of shNS-1 and shE7 expressing TC-1 cells are 
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shown. The images are representative of at least 25-50 individual cells. Scale bars = 10 μm. (C) 
The ratio of FLAG (C-terminal) to MYC (N-terminal) expression in the nuclei of silenced cells 
transiently transfected with pcDNA3 FLAG-E7-MYC construct. The nuclear intensities of 
FLAG and MYC signals were measured by ImageJ software and FLAG/MYC ratio was 
calculated. Mean ± SEM; n > 40. P-value <0.0001 (***), compared to shNS-2. 
 
Fig 6. Detection of truncated protein in siRNA-treated cells.  HeLa cells were stably transfected 
with either HPV16E7 or FLAG-HPV16E7-MYC before being treated with siRNAs (40nM of 
si16E7 or controls) and the proteosomal inhibitor, MG132, before protein extraction.  FLAG-
16E7-Myc was immunoprecipitated and detected with anti-FLAG antibodies.   Size markers are 
indicated and a FLAG positive control protein is shown in lane 1.  
 
 
 
Supporting Information  
 
 
S1 Fig. siRNA cleaved mRNA is not evenly degraded. (A) Schematic representation of the 
cutsite of E7 specific siRNA, siE7 and PCR amplicons amplifying the 5’ and 3’ ends of E6/7 
mRNA. (B) Total RNA was extracted from control (untreated and non-targeting siRNA, siNS-1) 
or siE7 treated CaSki cells and analysed by relative quantitative RT-PCR (∆∆Ct method). P-
value <0.01 (**). 
 
S2 Fig. The 5’ cleavage product is more stable than the 3’ cleavage product in siRNA treated 
cells. qRT-PCR analysis of degradation kinetics of 5’ and 3’ ends of E6/7 mRNA in untreated 
(A); non-specific siRNA, siNS-1 (B); and E7 specific siRNA, siE7 (C) treated CaSki cells. After 
incubation in Actinomycin D (ActD) containing medium (5 μg/mL) for indicated time points, the 
levels of 5’ and 3’ ends of E6/7 mRNA were measured to determine their half-lives. The y axis 
depicts relative E6/7 mRNA expression. The x axis represents the time (h) after the addition of 
ActD. Mean ± SEM; n = 3. The half-lives of 5’ and 3’ ends of the E6/7 mRNA are similar in 
untreated CaSki cells. Although half-lives of 5’ and 3’ ends appear to be similar in case of siNS-
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
21 
 
1 treatment, the exact values remain undetermined. The 5’ E6/7 mRNA fragment was at least 
two times more stable when compared to the corresponding 3’ fragment in cells transfected with 
siE7. 
 
S3 Fig. EDTA treatment dissociates polyribosome assembly from E6/7 mRNA. Cytoplasmic 
lysates were prepared from cells treated with EDTA and fractionated on a sucrose density 
gradient. (A, B) Representative polyribosomal profiles of non-specific shRNA, shNS-1 and E6/7 
targeting shRNA, shE6 treated TC-1 cells. Absorbance was recorded at 254 nm during collection 
of each fraction. (C) Relative distribution of β-actin mRNA in cycloheximide (CHX) and EDTA 
treated TC-1 cells. Each fraction was processed for RNA extraction and subsequently analysed 
by qPCR. The amount of β-actin mRNA in each fraction is relative to the amount of spike-in 
RNA (in vitro transcribed B. subtilis RNA). Mean ± SEM; n = 3. 
 
S4 Fig. Full-length E6/7 is bound to less number of ribosomes. Relative distribution of the full 
length E6/7 mRNA in gradient fractions of cycloheximide treated shNS-1 (A) and shE6 (B) 
treated TC-1 cells. Each fraction was processed for RNA extraction and subsequently analysed 
by relative qPCR (∆∆Ct method) utilizing amplicon 6 described in Fig. 1A. The amount of E6/7 
mRNA in each fraction was relative to the amount of spike-in RNA (in vitro transcribed B. 
subtilis RNA). Mean ± SEM; n = 3. 
 
S5 Fig. C-terminally truncated proteins can be detected in siRNA treated cells. (A) Schematic 
depicting E7 gene tagged with FLAG tag on the 5’ end and MYC tag on the 3’ end. The cutsite 
of E7-specific siRNAs, siE7 and siE7 new have been indicated. (B) Confocal images of FLAG 
and MYC protein expression in control and treated cells. The pcDNA3 FLAG-E7-MYC 
construct was transiently expressed in TC-1 cells prior to transfection with E7 specific siRNAs, 
siE7 and siE7 new. Scale bars = 10 μm. The images are representative of at least 25 individual 
cells. (C) The nuclear intensities of FLAG and MYC signals were measured by ImageJ software 
and FLAG/MYC ratio in control and siRNA treated cells was calculated. Mean ± SEM; n > 40. 
P-values <0.0001 (***), compared to siNS-1. 
 
Supporting Tables. 
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Table S1 sh/siRNA target sites and sequences. 
 
Table S2 Primer sequences used for real-time quantitative RT-PCR analysis  
 
Table S3 Primer and probe sequences used for stem loop qPCR analysis  
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